Background: Molecular Tumor Boards (MTBs) for patient selection and assessment of treatment options were created for adequate precision medicine delivering. We evaluated the implementation of both the MTB of the region of Antwerp/Belgium and different next generation sequencing (NGS) panels e comprising panels performed on liquid biopsy specimens e in treatments selection. We present results concerning patients with lung cancer. Method: Patients with lung cancer progressing to standard treatments who underwent NGS of tumor tissue, cell-free circulating tumor DNA (ctDNA) or both were included. The MTB expressed either a positive or negative opinion for the inclusion of the patient in a clinical trial, in an expanded access or as part of a compassionate use program. The alterations found were matched with OncoKB levels (MSKCC) of evidence for alterationspecific treatments. Results: The MTB evaluated 38 lung cancer patients (NSCLC and SCLC) with at least one NGS panel available. Overall, the MTB proposed alteration-specific targeted therapy to 24 out of 38 patients (63.1%). In 13 patients (7 LUAD, 3 LUSC and 3 SCLC) with matched lbNGS and ttNGS, lbNGS and ttNGS detected, respectively, 26 and 10 point mutations: 2 mutations were detected only by the ttNGS, 18 only by the lbNGS and 8 by both of them. In this cohort the MTB could allocate 3 patients (23%) to a clinical trial even in the absence of a OncoKB recommendation level 3b. Discussion: NGS panels were reported to improve patients outcomes [i] - [ii] - [iii] . This is not confirmed by the SHIVA trial
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